742 related articles for article (PubMed ID: 17470162)
1. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
Tsukamoto T; Masumori N; Rahman M; Crane MM
Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
[TBL] [Abstract][Full Text] [Related]
2. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
Chung BH; Hong SJ; Cho JS; Seong DH
BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
[TBL] [Abstract][Full Text] [Related]
3. [Correlation of serum prostate specific antigen, the volume and the intravesical prostatic protrusion for diagnosing bladder outlet obstruction in patients with benign prostate hyperplasia].
Bantis A; Zissimopoulos A; Kalaytzis C; Giannakopoulos S; Sountoulides P; Agelonidou E; Voudalikakis C; Touloupidis S
Hell J Nucl Med; 2007; 10(2):138-43. PubMed ID: 17684595
[TBL] [Abstract][Full Text] [Related]
4. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
5. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
8. Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting.
O'Leary MP; Wei JT; Roehrborn CG; Miner M;
BJU Int; 2008 Jun; 101(12):1531-5. PubMed ID: 18445080
[TBL] [Abstract][Full Text] [Related]
9. Short term outcomes of high power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate.
Volkan T; Ihsan TA; Yilmaz O; Emin O; Selcuk S; Koray K; Bedi O
Eur Urol; 2005 Oct; 48(4):608-13. PubMed ID: 16135396
[TBL] [Abstract][Full Text] [Related]
10. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men.
Liu CC; Huang SP; Li WM; Wang CJ; Chou YH; Li CC; Huang CH; Wu WJ
Urology; 2007 Oct; 70(4):677-80. PubMed ID: 17991536
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement.
Mills IW; Crossland A; Patel A; Ramonas H
Eur Urol; 2007 Aug; 52(2):503-9. PubMed ID: 17343981
[TBL] [Abstract][Full Text] [Related]
12. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study.
Paick SH; Meehan A; Lee M; Penson DF; Wessells H
J Urol; 2005 Mar; 173(3):903-7. PubMed ID: 15711315
[TBL] [Abstract][Full Text] [Related]
13. [A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia].
Xu J; Qian WQ; Song JD
Zhonghua Nan Ke Xue; 2008 Jun; 14(6):533-7. PubMed ID: 18649754
[TBL] [Abstract][Full Text] [Related]
14. Natural history of lower urinary tract symptoms in Japanese men from a 15-year longitudinal community-based study.
Fukuta F; Masumori N; Mori M; Tsukamoto T
BJU Int; 2012 Oct; 110(7):1023-9. PubMed ID: 22233355
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a new treatment outcome score for men with LUTS.
Weiss JP; Blaivas JG; Tash Anger JA; Di Blasio CJ; Panagopoulos G; Gerboc J
Neurourol Urodyn; 2004; 23(2):88-93. PubMed ID: 14983416
[TBL] [Abstract][Full Text] [Related]
16. Natural history of lower urinary tract symptoms: preliminary report from a community-based Indian study.
Ganpule AP; Desai MR; Desai MM; Wani KD; Bapat SD
BJU Int; 2004 Aug; 94(3):332-4. PubMed ID: 15291862
[TBL] [Abstract][Full Text] [Related]
17. Relationship between lower urinary tract symptoms and objective measures of benign prostatic hyperplasia: a Chinese survey.
Wang JY; Liu M; Zhang YG; Zeng P; Ding Q; Huang J; He DL; Song B; Kong CZ; Pang J
Chin Med J (Engl); 2008 Oct; 121(20):2042-5. PubMed ID: 19080272
[TBL] [Abstract][Full Text] [Related]
18. Correlation of prostate volume with international prostate symptom score and quality of life in men with benign prostatic hyperplasia.
Agrawal CS; Chalise PR; Bhandari BB
Nepal Med Coll J; 2008 Jun; 10(2):104-7. PubMed ID: 18828432
[TBL] [Abstract][Full Text] [Related]
19. Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community dwelling men.
Corica FA; Jacobsen SJ; King BF; Bostwick DG; Jacobson DJ; Girman CJ; Lieber MM
J Urol; 1999 Mar; 161(3):831-4. PubMed ID: 10022695
[TBL] [Abstract][Full Text] [Related]
20. Baseline prostatic specific antigen does not predict the outcome of high energy transurethral microwave thermotherapy.
Laguna MP; Kiemeney LA; Debruyne FM; de la Rosette JJ
J Urol; 2002 Apr; 167(4):1727-30. PubMed ID: 11912397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
